S&P 500   5,073.40 (+0.08%)
DOW   38,947.66 (-0.31%)
QQQ   436.55 (+0.00%)
AAPL   180.81 (-0.19%)
MSFT   406.17 (-0.34%)
META   484.18 (+0.51%)
GOOGL   138.37 (+0.58%)
AMZN   173.29 (-0.82%)
TSLA   199.63 (+0.12%)
NVDA   790.35 (-0.07%)
NIO   5.74 (+1.59%)
AMD   177.20 (+0.68%)
BABA   77.87 (+1.78%)
T   16.78 (+1.08%)
F   12.01 (+0.50%)
MU   91.97 (+2.81%)
CGC   3.52 (+1.44%)
GE   153.50 (-0.82%)
DIS   108.97 (+1.20%)
AMC   4.63 (+4.04%)
PFE   27.00 (-0.66%)
PYPL   60.00 (+1.13%)
XOM   104.59 (+0.33%)
S&P 500   5,073.40 (+0.08%)
DOW   38,947.66 (-0.31%)
QQQ   436.55 (+0.00%)
AAPL   180.81 (-0.19%)
MSFT   406.17 (-0.34%)
META   484.18 (+0.51%)
GOOGL   138.37 (+0.58%)
AMZN   173.29 (-0.82%)
TSLA   199.63 (+0.12%)
NVDA   790.35 (-0.07%)
NIO   5.74 (+1.59%)
AMD   177.20 (+0.68%)
BABA   77.87 (+1.78%)
T   16.78 (+1.08%)
F   12.01 (+0.50%)
MU   91.97 (+2.81%)
CGC   3.52 (+1.44%)
GE   153.50 (-0.82%)
DIS   108.97 (+1.20%)
AMC   4.63 (+4.04%)
PFE   27.00 (-0.66%)
PYPL   60.00 (+1.13%)
XOM   104.59 (+0.33%)
S&P 500   5,073.40 (+0.08%)
DOW   38,947.66 (-0.31%)
QQQ   436.55 (+0.00%)
AAPL   180.81 (-0.19%)
MSFT   406.17 (-0.34%)
META   484.18 (+0.51%)
GOOGL   138.37 (+0.58%)
AMZN   173.29 (-0.82%)
TSLA   199.63 (+0.12%)
NVDA   790.35 (-0.07%)
NIO   5.74 (+1.59%)
AMD   177.20 (+0.68%)
BABA   77.87 (+1.78%)
T   16.78 (+1.08%)
F   12.01 (+0.50%)
MU   91.97 (+2.81%)
CGC   3.52 (+1.44%)
GE   153.50 (-0.82%)
DIS   108.97 (+1.20%)
AMC   4.63 (+4.04%)
PFE   27.00 (-0.66%)
PYPL   60.00 (+1.13%)
XOM   104.59 (+0.33%)
S&P 500   5,073.40 (+0.08%)
DOW   38,947.66 (-0.31%)
QQQ   436.55 (+0.00%)
AAPL   180.81 (-0.19%)
MSFT   406.17 (-0.34%)
META   484.18 (+0.51%)
GOOGL   138.37 (+0.58%)
AMZN   173.29 (-0.82%)
TSLA   199.63 (+0.12%)
NVDA   790.35 (-0.07%)
NIO   5.74 (+1.59%)
AMD   177.20 (+0.68%)
BABA   77.87 (+1.78%)
T   16.78 (+1.08%)
F   12.01 (+0.50%)
MU   91.97 (+2.81%)
CGC   3.52 (+1.44%)
GE   153.50 (-0.82%)
DIS   108.97 (+1.20%)
AMC   4.63 (+4.04%)
PFE   27.00 (-0.66%)
PYPL   60.00 (+1.13%)
XOM   104.59 (+0.33%)
NASDAQ:TBIO

Telesis Bio (TBIO) Stock Price, News & Analysis

$0.53
-0.13 (-19.71%)
(As of 02:06 PM ET)
Today's Range
$0.50
$0.61
50-Day Range
$0.31
$0.78
52-Week Range
$0.30
$3.32
Volume
435,754 shs
Average Volume
1.13 million shs
Market Capitalization
$15.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Telesis Bio MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.05mentions of Telesis Bio in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.16) to ($0.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.85 out of 5 stars

Medical Sector

616th out of 943 stocks

Analytical Instruments Industry

19th out of 28 stocks


TBIO stock logo

About Telesis Bio Stock (NASDAQ:TBIO)

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system, including BioXp 3250 system, BioXp 9600 system, and BioXp DBC, which are empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits, such as BioXp De Novo kits, BioXp select kits, BioXp next generation sequencing kits, and BioXp DBC kits, which contains building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and short oligo ligation assembly enzymatic DNA synthesis designs to significantly reduce timelines for constructing synthetic DNA, RNA, and proteins compared to traditional chemical synthesis, paving the way for more efficient and effective development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

TBIO Stock Price History

TBIO Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Why Is Telesis Bio (TBIO) Stock Up 29% Today?
Telesis Bio, Inc. (TBIO)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Telesis Bio Appoints William Kullback CFO
Telesis Bio appoints William Kullback as CFO
Telesis Bio Appoints William J. Kullback Chief Financial Officer
Telesis Bio (TBIO) Receives a Rating Update from a Top Analyst
Telesis Bio: Q2 Earnings Snapshot
Telesis Bio (NASDAQ: DNAY)
Telesis Bio Inc (TBIO)
See More Headlines
Receive TBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telesis Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
2/27/2024
Next Earnings (Estimated)
3/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:TBIO
Previous Symbol
NASDAQ:DNAY
Fax
N/A
Employees
223
Year Founded
N/A

Profitability

Net Income
$-48,470,000.00
Net Margins
-127.49%
Pretax Margin
-127.14%

Debt

Sales & Book Value

Annual Sales
$30.00 million
Book Value
$1.58 per share

Miscellaneous

Free Float
20,689,000
Market Cap
$15.59 million
Optionable
Optionable
Beta
1.61
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Todd R. Nelson MBA (Age 57)
    Ph.D., CEO & Director
    Comp: $924.38k
  • Mr. Daniel G. Gibson Ph.D. (Age 47)
    Chief Technology Officer
    Comp: $590.37k
  • Mr. Robert H. Cutler (Age 56)
    Chief Legal Officer
    Comp: $568.58k
  • Mr. Eric Esser (Age 56)
    President & COO
  • Mr. William J. Kullback (Age 64)
    Chief Financial Officer
  • Ms. Jen Carroll
    Vice President of Investor Relations
  • Ms. Laura B. Puga M.B.A. (Age 44)
    Vice President of People & Culture
  • Mr. Decky Goodrich M.B.A.
    Senior Vice President of Commercial Operations
  • Mr. Laurence Warden
    Senior Vice President of Engineering & Instrumentation
  • Richard Lepke
    Director of Investor Relations














TBIO Stock Analysis - Frequently Asked Questions

How have TBIO shares performed in 2024?

Telesis Bio's stock was trading at $0.3990 at the beginning of 2024. Since then, TBIO shares have increased by 30.3% and is now trading at $0.5199.
View the best growth stocks for 2024 here
.

Are investors shorting Telesis Bio?

Telesis Bio saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 159,100 shares, a drop of 66.9% from the January 15th total of 481,200 shares. Based on an average daily trading volume, of 272,300 shares, the days-to-cover ratio is presently 0.6 days. Approximately 1.8% of the shares of the stock are sold short.
View Telesis Bio's Short Interest
.

When is Telesis Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024.
View our TBIO earnings forecast
.

How were Telesis Bio's earnings last quarter?

Telesis Bio, Inc. (NASDAQ:TBIO) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.06. The business had revenue of $2.79 million for the quarter, compared to the consensus estimate of $2.93 million. Telesis Bio had a negative net margin of 127.49% and a negative trailing twelve-month return on equity of 118.72%.

What guidance has Telesis Bio issued on next quarter's earnings?

Telesis Bio updated its fourth quarter 2023 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.0 million-$7.0 million, compared to the consensus revenue estimate of $9.5 million.

What is Craig J. Tuttle's approval rating as Telesis Bio's CEO?

13 employees have rated Telesis Bio Chief Executive Officer Craig J. Tuttle on Glassdoor.com. Craig J. Tuttle has an approval rating of 5% among the company's employees. This puts Craig J. Tuttle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Telesis Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Telesis Bio investors own include Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE), Moderna (MRNA), Johnson & Johnson (JNJ), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and VBI Vaccines (vbiv).

When did Telesis Bio IPO?

(TBIO) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO.

Who are Telesis Bio's major shareholders?

Telesis Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bridgeway Capital Management LLC (0.22%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Telesis Bio?

Shares of TBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TBIO) was last updated on 2/27/2024 by MarketBeat.com Staff